NCT05691465 - Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 27, 2023

Primary Completion Date

November 1, 2025

Study Completion Date

November 1, 2025

Conditions

Metastatic Prostate Adenocarcinoma With Neuroendocrine DifferentiationMetastatic Prostate Neuroendocrine CarcinomaMetastatic Prostate Small Cell Neuroendocrine CarcinomaStage IV Prostate Cancer AJCC v8

Interventions

PROCEDURE

Biospecimen Collection

Undergo collection of blood

PROCEDURE

Computed Tomography

Undergo CT scan

RADIATION

Gallium Ga 68-DOTATATE

Given IV

DRUG

Lutetium Lu 177 Dotatate

Given IV

PROCEDURE

Positron Emission Tomography

Undergo PET

Trial Locations (13)

21287

RECRUITING

Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore

27157

RECRUITING

Wake Forest University Health Sciences, Winston-Salem

40536

RECRUITING

University of Kentucky/Markey Cancer Center, Lexington

43210

RECRUITING

Ohio State University Comprehensive Cancer Center, Columbus

53718

RECRUITING

University of Wisconsin Carbone Cancer Center - Eastpark Medical Center, Madison

53792

RECRUITING

University of Wisconsin Carbone Cancer Center - University Hospital, Madison

60611

RECRUITING

Northwestern University, Chicago

75390

RECRUITING

UT Southwestern/Simmons Cancer Center-Dallas, Dallas

77030

RECRUITING

M D Anderson Cancer Center, Houston

90033

RECRUITING

Los Angeles General Medical Center, Los Angeles

RECRUITING

USC / Norris Comprehensive Cancer Center, Los Angeles

91010

RECRUITING

City of Hope Comprehensive Cancer Center, Duarte

95817

RECRUITING

University of California Davis Comprehensive Cancer Center, Sacramento

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH